Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study Evaluating the Safety, Tolerability, PK, Immunogenicity, and Clinical Response of Multiple Doses of IV AK006 in Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001

NCT06577116 is registered in ClinicalTrials.gov with Allakos Inc. as lead sponsor.

NCT NCT06577116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06577116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study Evaluating the Safety, Tolerability, PK, Immunogenicity, and Clinical Response of Multiple Doses of IV AK006 in Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001
Lead sponsor
Allakos Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 28, 2024
Completion date
May 21, 2025
Enrollment
29 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria